Keyword Search Year None202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001 11/25/24 Alkermes to Participate in Upcoming Investor Conferences 11/11/24 Alkermes to Participate in Two Upcoming Investor Conferences 11/07/24 Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences 10/24/24 Alkermes plc Reports Third Quarter 2024 Financial Results 10/17/24 Alkermes to Report Third Quarter Financial Results on October 24, 2024 09/25/24 Alkermes to Host Investor Event to Review Orexin Portfolio Strategy 09/23/24 Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024 09/19/24 Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference 09/13/24 Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program 08/28/24 Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference 08/22/24 Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 07/24/24 Alkermes plc Reports Second Quarter 2024 Financial Results 07/17/24 Alkermes to Report Second Quarter Financial Results on July 24, 2024 06/03/24 Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024 05/29/24 Alkermes to Participate in Two Upcoming Investor Conferences 05/28/24 Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 05/14/24 Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences 05/02/24 Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk 05/01/24 Alkermes plc Reports First Quarter 2024 Financial Results 04/24/24 Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 04/17/24 Alkermes to Report First Quarter Financial Results on May 1, 2024 04/09/24 Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia 04/08/24 Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society 03/07/24 Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors 02/15/24 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 02/08/24 Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024 01/03/24 Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference 01/03/24 Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)
11/07/24 Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences
09/23/24 Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024
09/19/24 Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference
08/22/24 Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2
06/03/24 Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
05/14/24 Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
04/24/24 Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
04/09/24 Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
04/08/24 Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
02/15/24 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
01/03/24 Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)
